X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Cipla with Cadila Healthcare - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

CIPLA vs CADILA HEALTHCARE - Comparison Results

CIPLA    Change

Cipla is one of the largest pharma companies in the domestic market and has presence in formulations and bulk drugs manufacturing. All the bulk drug manufacturing facilities of the company have been approved by various authorities including the US FD... More

CADILA HEALTHCARE 
   Change

Cadila Healthcare is one of the leading players in the Indian pharma market having a presence in both the domestic and international markets. In the international markets, the company had adopted the strategy of competing directly in the generics mar... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    CIPLA CADILA HEALTHCARE CIPLA/
CADILA HEALTHCARE
 
P/E (TTM) x 44.8 32.3 138.9% View Chart
P/BV x 3.8 6.0 64.0% View Chart
Dividend Yield % 0.3 0.8 42.6%  

Financials

 CIPLA   CADILA HEALTHCARE
EQUITY SHARE DATA
    CIPLA
Mar-17
CADILA HEALTHCARE
Mar-17
CIPLA/
CADILA HEALTHCARE
5-Yr Chart
Click to enlarge
High Rs622460 135.2%   
Low Rs458305 150.3%   
Sales per share (Unadj.) Rs181.992.1 197.4%  
Earnings per share (Unadj.) Rs12.914.8 86.9%  
Cash flow per share (Unadj.) Rs29.318.5 158.6%  
Dividends per share (Unadj.) Rs2.003.20 62.5%  
Dividend yield (eoy) %0.40.8 44.3%  
Book value per share (Unadj.) Rs155.768.0 229.0%  
Shares outstanding (eoy) m804.511,023.74 78.6%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x3.04.2 71.5%   
Avg P/E ratio x42.025.8 162.6%  
P/CF ratio (eoy) x18.420.7 89.0%  
Price / Book Value ratio x3.55.6 61.7%  
Dividend payout %15.521.6 72.0%   
Avg Mkt Cap Rs m434,516391,581 111.0%   
No. of employees `00023.016.9 136.7%   
Total wages/salary Rs m26,33815,002 175.6%   
Avg. sales/employee Rs Th6,349.15,594.5 113.5%   
Avg. wages/employee Rs Th1,143.0890.1 128.4%   
Avg. net profit/employee Rs Th449.3899.9 49.9%   
INCOME DATA
Net Sales Rs m146,30294,295 155.2%  
Other income Rs m2,2871,286 177.8%   
Total revenues Rs m148,58995,581 155.5%   
Gross profit Rs m24,75819,036 130.1%  
Depreciation Rs m13,2293,750 352.8%   
Interest Rs m1,594450 354.2%   
Profit before tax Rs m12,22216,122 75.8%   
Minority Interest Rs m0338 0.0%   
Prior Period Items Rs m-700-   
Extraordinary Inc (Exp) Rs m0-3 0.0%   
Tax Rs m1,7981,289 139.5%   
Profit after tax Rs m10,35415,168 68.3%  
Gross profit margin %16.920.2 83.8%  
Effective tax rate %14.78.0 184.0%   
Net profit margin %7.116.1 44.0%  
BALANCE SHEET DATA
Current assets Rs m87,37060,223 145.1%   
Current liabilities Rs m33,08153,058 62.3%   
Net working cap to sales %37.17.6 488.4%  
Current ratio x2.61.1 232.7%  
Inventory Days Days8770 124.5%  
Debtors Days Days6288 70.7%  
Net fixed assets Rs m111,56772,984 152.9%   
Share capital Rs m1,6091,024 157.1%   
"Free" reserves Rs m123,64568,576 180.3%   
Net worth Rs m125,25469,600 180.0%   
Long term debt Rs m36,45424,684 147.7%   
Total assets Rs m209,532152,207 137.7%  
Interest coverage x8.736.8 23.5%   
Debt to equity ratio x0.30.4 82.1%  
Sales to assets ratio x0.70.6 112.7%   
Return on assets %5.710.3 55.6%  
Return on equity %8.321.8 37.9%  
Return on capital %8.517.9 47.4%  
Exports to sales %34.20-   
Imports to sales %8.30-   
Exports (fob) Rs m50,050NA-   
Imports (cif) Rs m12,203NA-   
Fx inflow Rs m51,06621,280 240.0%   
Fx outflow Rs m17,67810,874 162.6%   
Net fx Rs m33,38810,406 320.9%   
CASH FLOW
From Operations Rs m23,82413,495 176.5%  
From Investments Rs m-13,127-29,103 45.1%  
From Financial Activity Rs m-13,23923,158 -57.2%  
Net Cashflow Rs m-2,4787,556 -32.8%  

Share Holding

Indian Promoters % 16.0 74.8 21.4%  
Foreign collaborators % 20.8 0.0 -  
Indian inst/Mut Fund % 12.2 8.3 147.0%  
FIIs % 23.7 5.9 401.7%  
ADR/GDR % 1.1 0.0 -  
Free float % 26.2 11.0 238.2%  
Shareholders   161,166 44,069 365.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare CIPLA With:   PIRAMAL ENTERPRISES  NOVARTIS  DR. DATSONS LABS  MERCK LTD  GSK PHARMA  

Compare CIPLA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Indian Indices Trade Marginally Higher; IT Stocks Witness Buying Interest(11:30 am)

Stock markets in India are presently trading marginally higher. Sectoral indices are trading on a mixed note with stocks in the IT sector and consumer durables sector witnessing maximum buying interest.

Related Views on News

Cipla: Strong Recovery Post GST (Quarterly Results Update - Detailed)

Nov 10, 2017

Cipla's India business recovers strongly this quarter post the GST issues in the first quarter of this fiscal.

Cipla: Extraordinary Income Boosts Net Profits (Quarterly Results Update - Detailed)

Oct 30, 2017

Proceeds from the sale of the South African animal business bolstered Cipla's net profits for the quarter.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

Follow India's Super Investors to Make Big Money in the Market Crash(The 5 Minute Wrapup)

Feb 8, 2018

Has the sell-off in the markets left India's super investors unduly worried?

The Era of Easy Money is Coming to an End. What Happens Now?(Vivek Kaul's Diary)

Feb 9, 2018

The easy money policy of the Federal Reserve of the United States, which drove up stock markets all over the world, is ending, with the Federal Reserve looking to shrink its balance sheet.

The Markets Want Your Money. Don't Give It to Them.(Smart Contrarian)

Feb 9, 2018

MFs are having a gala time taking money from over-eager investors and funneling it into equities. Smart investors, though, know better than to do that.

The Big Gamble(The Honest Truth)

Feb 15, 2018

Once you accept the fact that elections are round the corner and that this budget is geared to reach a 40% target, everything makes sense.

Rising Dominance of Mutual Funds(Chart Of The Day)

Feb 8, 2018

Domestic money flow into Indian equities surpassed foreign fund flows in the recent years. But will it continue in volatile market?

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

CIPLA SHARE PRICE


Feb 20, 2018 12:55 PM

TRACK CIPLA

CIPLA - FDC LTD. COMPARISON

COMPARE CIPLA WITH

MARKET STATS